Podcasts about tavr

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with CTSNet JANS Editor Dr. Mateo Marin-Cuartas, a cardiac surgeon in the University Department of Cardiac Surgery at the Leipzig Heart Center, Germany, about surgical aortic valve replacement (SAVR) vs transcatheter aortic valve replacement (TAVR). Chapters 00:00 Intro 00:57 Dr. Marin-Cuartas Feature 02:28 SHURUI Robot Feasability 05:09 Touching as Diagnostic Test 09:06 Removal of Rib Stab Hardware 13:00 Resectable EGFR-Positive NSCLC 16:12 On-Pump Beating Heart MVR 17:56 Post-Infarction Myocardial Rupture 19:52 Head-First Graft Technique 22:18 SAVR vs TAVR, Dr. Marin-Cuartas 46:44 Upcoming Events 47:52 Closing They discuss SAVR and TAVR guidelines, the suitability of SAVR vs TAVR for patients aged 65-75, and mechanical heart valves. They also explore surgery after TAVR, TAVR after TAVR, and the future of addressing aortic valve stenosis.   Joel also highlights recent JANS articles on the safety and feasibility of novel single-port robotic-assisted lobectomy/segmentectomy for lung cancer, touching (proximity) as a companion diagnostic test, long-term outcomes after removal of rib stabilization hardware in patients with blunt chest trauma, and advancing the needle on the management of resectable EGFR-positive NSCLC.    In addition, Joel explores an on-pump beating heart mitral valve repair through right anterior minithoracotomy, post-infarction myocardial rupture treated with surgical repair and graded mechanical support, and a head-first graft technique in aortic arch replacement. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer  2.) Touching (Proximity) as a Companion Diagnostic Test   3.)  Long-Term Outcomes After Removal of Rib Stabilization Hardware in Patients With Blunt Chest Trauma  4.) Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?  CTSNET Content Mentioned  1.) On-Pump Beating Heart Mitral Valve Repair Through Right Anterior Mini Thoracotomy  2.) Drain, Patch, Unload: Post-Infarction Myocardial Rupture Treated With Surgical Repair and Graded Mechanical Support  3.) Head-First Graft Technique in Aortic Arch Replacement  Other Items Mentioned  1.) Career Center   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this episode, Thomas Draper, Vice President of the Wellstar Center for Cardiovascular Care, joins Becker's to discuss how Transcatheter Aortic Valve Replacement (TAVR) has evolved into a cornerstone of structural heart programs. Tom shares how Wellstar built a multidisciplinary infrastructure around TAVR, leveraged data and AI to identify underserved patients, and embraced technology to maintain quality amid rapid growth. Tune in to hear how the expansion of TAVR indications, AI integration, and patient-centered strategy are shaping the future of cardiovascular care.This episode is sponsored by Edwards Lifesciences.

Supra-Annular Vs. Intra-Annular Devices For TAVR-in-TAVR: The Pandora International Registry

In this special one-year anniversary episode of The Atrium, host Dr. Alice Copperwheat speaks with Dr. Michael Mack, medical director of cardiothoracic surgery at Baylor Scott and White Health System and chairman of the Baylor Plano Research Center in Texas, about the future of valve surgery. Chapters 00:00 Introductions 01:18 Dr. Mack Background 03:41 Becoming a CT Surgeon 07:53 Path to Academic Surgery 10:19 Unconventional Thinking 11:30 TAVR vs SAVR 21:54 Surgical Replacement Future 25:59 Minimally Invasive Preference 27:27 Long-Term Data Impact 30:58 Aortic Valve Research Status 35:35 Mitral Clip vs Repair, Tricuspid 41:40 Mitral Robotic 44:38 Artificial Intelligence 48:43 Specializing Your Career 52:53 Three Career Tips They discuss transcatheter aortic valve replacement (TAVR), surgical aortic valve replacement (SAVR), MitraClips, the mitral valve, and the tricuspid valve. They also explore future research, the role of artificial intelligence (AI) and Dr. Mack provides advice for trainees.   The Atrium is a monthly podcast presenting clinical and career-focused topics for residents and early career professionals across all cardiothoracic surgery subspecialties. Watch for next month's episode on radial artery harvesting with Dr. Faisal Bakaeen of the Cleveland Clinic. Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Evaluating Coronary Access After TAVR With The 4th And 5th -generation Self-expanding Valves - The EPROMPT-CA Study

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning celebrates two years of the podcast and speaks with Dr. Joseph F. Sabik III, president of the Society of Thoracic Surgeons (STS) and chair of the Department of Surgery at University Hospitals Cleveland Medical Center, about the future of cardiothoracic surgery. Chapters 00:00 Intro 01:16 Dr. Sabik Guest 04:13 AATS 2025 20:26 Extended Sleeve Lobectomy Study 23:55 SQUAT Trial Results 26:28 TAVR vs SAVR in Women 27:49 Transition from Training to Practice 31:39 Totally Endoscopic Triple Valve 33:33 Redo AVR via Ministernotomy 35:18 ECMO Podcast Episode 37:19 Dr. Sabik, Future of CT Surgery 56:06 Upcoming Events 57:47 Closing They discuss the future of revascularization, advancements in valve procedures, arterial grafting, robotics training, and the importance of work-life balance. They also highlight the training of the next generation of surgeons, simulation-based education, and Dr. Sabik shares insights into the 62nd STS Annual Meeting. Additionally, Joel recaps the American Association for Thoracic Surgery (AATS) Annual Meeting emphasizing notable presentations and key insights from the event.   Joel also highlights recent JANS articles on extended sleeve lobectomy after neoadjuvant immunochemotherapy for centrally located non-small cell lung cancer, neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable Stage III N2 NSCLC, transcatheter vs. surgical aortic valve replacement in women, and a guide for transition from cardiothoracic surgery training to practice.   In addition, Joel explores totally endoscopic triple valve surgery, redo aortic valve replacement through a ministernotomy, and a new podcast episode from Dr. Alice Copperwheat, “The Atrium: ECMO,” with expert guest Dr. Jose Fernandes. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-Small Cell Lung Cancer  2.)  Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)   3.) Transcatheter vs. Surgical Aortic Valve Replacement in Women: The RHEIA Trial  4.) A Guide for Transition from Cardiothoracic Surgery Training to Practice  CTSNET Content Mentioned  1.) Totally Endoscopic Triple Valve Surgery: AVR, MVr, TVr  2.) Redo Aortic Valve Replacement Through a Ministernotomy    3.) The Atrium: ECMO  Other Items Mentioned  1.) Webinar Series: Women in Cardiothoracic Surgery—Advancement Through Collaboration   2.) Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach  3.) Aortic Valve Replacement Series   4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I  FDA announces approval for TAVR in pts with asymptomatic AS Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880 EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9 II PPG that Can Distinguish source of Tachycardia Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798 III PRAETORIAN -XL trial Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576 Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932 Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917 The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156 IV Stroke in Young People Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855 Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Mario Castillo-Sang, the Surgical Director of Mitral Valve and Heart Failure Therapies at St. Elizabeth Healthcare, Edgewood, Kentucky, USA, about totally endoscopic cardiac surgery. Chapters 00:00 Intro 01:17 Minimal Access Bedside Cardiac 04:37 Lung Cancer, Histological Subtype 09:29 TAVR vs SAVR, AS & CAD 12:22 Biopros TVR Outcomes 15:48 Mitral Annular Disjunction, MVR 18:47 Ozaki Technique, AV Reconst 20:46 Redo LVOT Reconst for Endocarditis 22:33 Totally Endoscopic ASD Closure TVR 24:08 Dr. Castillo-Sang, MI Bedside Endoscopy 40:51 Closing They explore key highlights from Dr. Castillo-Sang's CTSNet series Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach, his journey in performing endoscopic surgeries, and how he learned the techniques. Dr. Castillo-Sang shares the advantages of endoscopic surgery, as well as tips and recommendations for those wanting to learn this approach. He emphasizes the importance of the instruments he has worked with, detailing how these have improved over time. Additionally, they explore Dr. Castillo-Sang's involvement with the Endoscopic Cardiac Surgeons Club, discussing how he got involved and providing details about the club's upcoming annual meeting.   Joel also highlights recent JANS articles on the estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time, transcatheter vs surgical aortic valve replacement in Medicare beneficiaries with aortic stenosis and coronary artery disease, long-term outcomes after bioprosthetic tricuspid valve replacement, and outcomes of patients with mitral annular disjunction undergoing mitral valve repair.  In addition, Joel explores aortic valve reconstruction using the Ozaki technique, redo LVOT reconstruction for endocarditis, and totally endoscopic ASD closure with tricuspid valve repair. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Estimated Worldwide Variation and Trends in Incidence of Lung Cancer by Histological Subtype in 2022 and Over Time: A Population-Based Study  2.) Transcatheter vs Surgical Aortic Valve Replacement in Medicare Beneficiaries With Aortic Stenosis and Coronary Artery Disease  3.) Long-Term Outcomes After Bioprosthetic Tricuspid Valve Replacement: A Multicenter Study  4.) Outcomes of Patients With Mitral Annular Disjunction Undergoing Mitral Valve Repair  CTSNET Content Mentioned  1.) Aortic Valve Reconstruction—The Ozaki Technique  2.) Redo LVOT Reconstruction for Endocarditis  3.) Totally Endoscopic ASD Closure With Tricuspid Valve Repair  Other Items Mentioned  1.) Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach  2.) Endoscopic Cardiac Surgeons Club  3.) Mini Heart Valves   4.) Aortic Valve Replacement Series     5.) Career Center 6.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I FAME 3 at Five Years Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4 Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299 Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057 II TAVR in Low-Risk Patients at 5 years 5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004 EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428 PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447 NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606 III The Matter of Pacemakers After TAVI JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028 Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals   IV Mavacamten Looks to Have Specific Indications EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050 BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/ FINAL THOUGHTS PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Program notes:0:33 TAVR outcomes improved1:33 Dapagliflozin 2:33 Looked at comorbidities3:00 Tolebrutinib for relapsing MS4:00 Annualized relapse rate5:00 Works in the CNS6:00 First endpoint wasn't proven6:20 Invasive group A strep7:20 Become more resistant to antibiotics8:01 Not a single type of group A strep8:25 Hearing loss and heart failure9:25 Psychological distress mediiates10:25 With hearing aids, you would think it would go down11:20 Everything looks associated12:03 End

In this podcast, Dr. Valentin Fuster presents a comprehensive review of conduction disturbances following transcatheter aortic valve replacement (TAVR), highlighting key factors that contribute to the need for permanent pacemaker implantation. The discussion covers current management strategies, risks, and future perspectives, emphasizing the need for improved prediction methods and the evolving role of ambulatory monitoring and physiological pacing techniques.

In this podcast, Dr. Valentin Fuster reviews a pivotal study comparing the five-year outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis. The study found that both treatments yielded similar mortality and stroke rates, reinforcing TAVR's non-inferiority to surgery, though long-term outcomes in younger patients and the impact of pacemaker implantation remain areas of concern.

I'm delighted to bring you Episode 4 of Season 3 of The Luke Coutinho Show, featuring Dr. Maulik Parekh—a leading Interventional Cardiologist, Head of the TAVR and Structural Heart Programme, and Consultant at the Sir H. N. Reliance Foundation Hospital and Research Centre.Tune in to discover:Dr. Maulik's journey into cardiology: From aspiring architect to pioneering cardiologist, and healing through groundbreaking structural heart interventions for all agesUnderstanding the rising incidence of heart diseases: Why India is facing an alarming rise in heart issues among the young, driven by genes, lifestyle, and stressGenetics vs. Epigenetics: How can you outsmart your family history with the right choicesPreventive heart health: Recommended screenings for all age groups and mindful use of health tracking devicesImpact of chronic stress and emotions on heart health: How stress and emotions can disrupt rhythms, weaken muscles, and turn minor plaques into major heart attacksMeditation and body awareness: Learn to deepen your connection to heart health by enhancing sensitivity to your body's pulse and cardiovascular stateVaping, stimulants, and heart health: Vaping and stimulants hijack your heart's natural rhythm, leading to long-term cardiac stress and dysfunctionAnd much more…Chapters:00:00 - Introduction and Dr. Maulik's Journey06:55 - Rise in Young Heart Attacks10:35 - Genetics vs. Epigenetics13:23 - Essential Heart Health Screenings20:09 - Health Gadgets: Helpful or Stressful?23:51 - Dr. Maulik's Personal Health Routine30:26 - How Stress Damages Your Heart34:38 - Broken Heart Syndrome Explained37:06 - Meditation and Body Awareness40:28 - Vaping, Stimulants & Heart Health44:26 - The Four C's for Heart Health

Makoto Mori, MD, JACC: Associate Editor, is joined by author John K. Forrest, MD, FACC, discussing this study from Forrest et al presented at ACC.25 and published in JACC. Patients with severe aortic stenosis who were treated with either a supraannular self-expanding TAVR or surgery showed comparable rates of all-cause mortality and disabling stroke at 5 years, strengthening TAVR as a safe, effective, and durable alternative to surgery for patients, regardless of their surgical risk.

In this podcast, Dr. Valentin Fuster presents a study evaluating the five-year outcomes of Transcatheter Aortic Valve Replacement (TAVR) versus surgical aortic valve replacement in high-risk patients. The study shows that TAVR leads to significantly better valve performance but highlights that both procedures' long-term success is hindered by bioprosthetic valve dysfunction, underscoring the need for individualized treatment strategies and longer follow-up studies.

In this episode, Dr. Valentin Fuster presents key findings from the April 8, 2025 issue of the Journal of the American College of Cardiology, covering three groundbreaking studies. Topics include the newly defined threshold for mild aortic stenosis using MRI, the relationship between heat wave exposure and cardiac mortality, and the long-term outcomes of aortic valve performance in patients undergoing TAVR versus surgery.

Guest: Craig Smith, MD On this episode of Advances in Care, host Erin Welsh and Dr. Craig Smith, Chair of the Department of Surgery and Surgeon-in-Chief at NewYork-Presbyterian and Columbia discuss the highlights of Dr. Smith's 40+ year career as a cardiac surgeon and how the culture of Columbia has been a catalyst for innovation in cardiac care. Dr. Smith describes the excitement of helping to pioneer the institution's heart transplant program in the 1980s, when it was just one of only three hospitals in the country practicing heart transplantation. Dr. Smith also explains how a unique collaboration with Columbia's cardiology team led to the first of several groundbreaking trials, called PARTNER (Placement of AoRTic TraNscatheteR Valve), which paved the way for a monumental treatment for aortic stenosis — the most common heart valve disease that is lethal if left untreated. During the trial, Dr. Smith worked closely with Dr. Martin B. Leon, Professor of Medicine at Columbia University Irving Medical Center and Chief Innovation Officer and the Director of the Cardiovascular Data Science Center for the Division of Cardiology. Their findings elevated TAVR, or transcatheter aortic valve replacement, to eventually become the gold-standard for aortic stenosis patients at all levels of illness severity …

In this podcast highlights the growing concern over transcatheter valve failure following transcatheter aortic valve replacement (TAVR), emphasizing the need for standardized imaging protocols and frequent follow-ups. Experts discuss best practices for monitoring and managing these patients, urging collaborative international efforts to validate new imaging techniques and improve patient outcomes.

Listener feedback on asymptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR), coronary artery calcium (CAC), and revascularization for patients with ischemic LV dysfunction are discussed by John Mandrola, MD, in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Aortic Valve Intervention for Asymptomatic AS Asymptomatic Aortic Stenosis: “Time to Act” or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9 EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec Reddy et al: https://doi.org/10.1016/j.jacc.2024.12.031 Wallach editorial https://doi.org/10.1016/j.jacc.2025.01.020 Guerrero https://www.tctmd.com/slide/tavr-young-patients-current-treatment-patterns-us II CAC - Coronary Artery Calcium Coronary Artery Calcium Testing—Too Early, Too Late, Too Often https://jamanetwork.com/journals/jamacardiology/fullarticle/2830950 CAUGHT-CAD https://jamanetwork.com/journals/jama/fullarticle/2831115 III CABG, PCI or Meds for Ischemic LV Dysfunction STICH https://www.nejm.org/doi/full/10.1056/NEJMoa1100356 STICHES https://www.nejm.org/doi/full/10.1056/NEJMoa1602001 REVIVED BCIS https://www.nejm.org/doi/full/10.1056/NEJMoa2206606 EHJ paper https://doi.org/10.1093/eurheartj/ehaf080 IV Preview https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

The field of transcatheter aortic valve replacement (TAVR) continues to evolve, with new research expanding its indications and refining its application. This JACC special issue brings together cutting-edge studies, meta-analyses, and expert perspectives on key topics shaping the future of TAVR. Highlights include pivotal trials assessing TAVR in low-risk patients, a growing focus on moderate aortic stenosis and heart failure, and novel insights into reintervention strategies. The issue also presents comprehensive analyses on asymptomatic severe aortic stenosis, valve durability, and patient selection for next-generation TAVR applications. As TAVR increasingly moves beyond its initial role in high-risk patients, the studies featured here provide essential data to guide clinical decision-making, optimize outcomes, and address the challenges of valve longevity, structural durability, and patient-centric approaches. We hope this collection informs and inspires continued innovation in structural heart disease management.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826241296671

In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that's approaching the complicated and competitive TAVR market. Chris Newsmaker and Host Tom Salemi also discuss this week's Newmarker's Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA. This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

Welcome to a special re-run of Doc Talk! Today, we're revisiting Episode 30—Time for TAVR with Dr. Joseph Tuma—just in time for Heart Valve Disease Awareness Day, happening February 21st from 4 to 6 PM at Monument Health Rapid City Hospital.TAVR, or Transcatheter Aortic Valve Replacement, is a groundbreaking procedure for those with aortic valve disease. If you or someone you love is at risk, this episode is a must-listen. Hosted on Acast. See acast.com/privacy for more information.

On this episode of The Medical Alley Podcast, we have a conversation with Wayne Paterson, CEO and Managing Director of Anteris Technologies.In late December of 2024, Anteris Technologies launched an IPO to support the development of DurAVR, a Transcatheter Heart Valve (THV) designed to treat aortic stenosis. Wayne discusses the IPO and DurAVR's development, the future of Anteris Technologies, and why the company has chosen Minnesota as the site of its global headquarters.Send us a message!Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

Aortic Valve Prosthesis Selection   Guest: Kimberly Holst, M.D. Host: Sharonne Hayes, M.D.   In this podcast we will learn to identify patient specific factors to be considered during evaluation for aortic valve replacement including patient specific anatomy, comorbidities, and lifelong management of aortic valve disease. Learners will learn to identify advantages to mechanical and biologic prostheses for management of aortic valve disease and identify areas of developing technology and treatment options for aortic valve disease.   Topics Discussed: What are the main factors to consider when evaluating a patient for aortic valve replacement?  What patient specific factors that may make a patient less suitable for transcatheter aortic valve replacement (TAVR)? What are the advantages of each mechanical and biologic prostheses in treatment of aortic valve disease? What new technologies are available for management of aortic valve disease?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

In this episode, Dr. Valentin Fuster discusses five key studies from the January 2025 JACC issue, covering advancements in coronary angioplasty, revascularization strategies for STEMI, machine learning for ICD patient outcomes, thromboxane's link to heart failure, and TAVR valve types and anesthesia approaches. These studies provide valuable insights into improving cardiovascular care and treatment.

In this episode, Dr. Valentin Fuster discusses the five-year results of the SOFT TAVI trial, which compared self-expanding and balloon-expanding valves for transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis. The findings reveal similar long-term outcomes for both valve types and anesthesia strategies, with subtle differences in stroke rates and pacemaker implantations, emphasizing the growing safety and efficacy of conscious sedation in TAVR procedures.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning discusses the robotic market. He explores the new FDA approval for the Johnson & Johnson robotic surgical system for clinical trials, the background of Johnson & Johnson MedTech, and the location for this trial. He also discusses the details of TAVR, what we currently know about TAVR, and highlights an article by Steve Bell that discusses his own views on Johnson & Johnson and the robotic market.    Joel also reviews recent JANS articles on The Society of Thoracic Surgeons expert consensus on the multidisciplinary management and resectability of locally advanced non-small cell lung cancer, a European multicenter study evaluating the prognosis of peripheral early-stage lung adenocarcinoma patients operated on by segmentectomy or lobectomy, early intervention in patients with asymptomatic severe aortic stenosis and myocardial fibrosis, and the use of hybrid stage I to stratify between single ventricle palliation and biventricular repair.   In addition, Joel explores an off-pump ASD closure with a two-layer patch attached to the right atrium, a repair of Scimitar syndrome in a two-year-old via VRAT, and robotic-assisted carinal reconstruction using cross table ventilation. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-small Cell Lung Cancer  2.) European Multicentre Study Evaluating the Prognosis of Peripheral Early-Stage Lung Adenocarcinoma Patients Operated on by Segmentectomy or Lobectomy  3.) Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED trial  4.) Use of Hybrid Stage I to Stratify Between Single Ventricle Palliation and Biventricular Repair  CTSNET Content Mentioned  1.) Off-Pump ASD Closure With a Two-Layer Patch Attached to the Right Atrium  2.) Repair of Scimitar Syndrome in a Two-Year-Old Via VRAT: Pitfalls of Intra-atrial Baffle  3.) Robotic-Assisted Carinal Reconstruction Using Cross Table Ventilation—A Novel Surgical Technique  Other Items Mentioned  Why am I so tough on Johnson & Johnson and Medtronic and their surgical robotic programs?  CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis

Join us as we review recent practice-changing articles on a new triple pill for hypertension, how arm position affects blood pressure, early TAVR for asymptomatic patients with severe AS, liberal versus restrictive transfusion strategy in patients with acute brain injury, and a quick overview of the 2024 ACC/AHA perioperative medicine guidelines. Fill your brain hole with a delicious stack of tofurkey cakes! Featuring Paul Williams (@PaulNWilliamz), Rahul Ganatra (@rbganatra), Jen DeSalvo (@drjendesalvo), and Matt Watto (@doctorwatto). Claim CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME! Credits Written and Hosted by: Rahul Ganatra MD, MPH; Jen DeSalvo MD; Paul Williams, MD, FACP, Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewer: Rahul Ganatra MD, MPH Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer A new triple pill for hypertension How arm position affects blood pressure Early TAVR for asymptomatic patients with severe AS Liberal versus restrictive transfusion strategy in patients with acute brain injury A quick overview of the 2024 ACC/AHA perioperative medicine guidelines Outro Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: AquaTru Today listeners receive 20% off any AquaTru purifier! Just go to AquaTru.com and enter code “CURB“ at checkout. Sponsor: Uncommon Goods To get 15% off your next gift, go to uncommongoods.com/curb.

In this episode of Structural Heart Talks, Larry Wood, Corporate VP and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart at Edwards Lifesciences, discusses the transformative journey of transcatheter aortic valve replacement (TAVR) and the SAPIEN valve. Wood reflects on the innovation that enables minimally invasive heart valve replacement, which has become the standard of care for severe aortic stenosis and offers patients faster recovery and greater independence. The conversation explores Edwards' efforts to expand access to TAVR, emphasizing the importance of reducing undertreatment and addressing outdated clinical guidelines that delay intervention. Wood also highlights findings from the recent early TAVR study, which challenges long-standing paradigms and advocates for changes to the guidelines to allow earlier treatment of aortic stenosis before symptoms appear. Thank you to Confluent Medical Technologies for sponsoring this episode of Structural Heart Talks. To learn more about how Confluent Medical supports medical device companies, visit: www.confluentmedical.com. Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

In this podcast, Editor-in-Chief Jian'an Wang discusses the ongoing debate over patient-prosthesis mismatch (PPM) following transcatheter aortic valve replacement (TAVR), highlighting conflicting findings between Western and Asian cohorts. Recent data from the updated Ocean TAVR registry suggests that severe PPM is an independent risk factor for long-term mortality and rehospitalization, underscoring the need for personalized device selection to improve outcomes, particularly in patients with smaller annuli and larger body surface areas.

In this episode of the JACC: Asia podcast, Cheol Hyun Lee explores the prognostic impact of patient-prosthesis mismatch (PPM) following transcatheter aortic valve replacement (TAVR) in Asian patients, who tend to have smaller annular sizes compared to Western populations. The study highlights that while severe PPM occurs in only 1.3% of patients, it is significantly linked to a higher risk of heart failure hospitalization, underscoring the need for personalized treatment approaches in Asia to reduce the risk of severe PPM.

Author Nicolas M. Van Mieghem, MD, PhD, FACC, and JACC: Executive Associate Editor Aakriti Gupta, MD, FACC,  discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

Author Joerg Hausleiter, MD and Executive Associate Editor Aakriti Gupta, MD, FACC. discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

A client had a complex surgical procedure on her heart two weeks prior, but it was conducted by way of a catheter threaded up her femoral artery and aorta. Now, she wants to receive massage again. A quick Google search suggests that it would be OK. Her MT is skeptical and wants to be more conservative. Who is right? Listen on for information about transcatheter aortic valve replacement (TAVR) surgery, using AI to make clinical decisions, and how to get to “yes” for people who have recently had surgery. Host Bio:                    Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.                    Resources:    Pocket Pathology: https://www.abmp.com/abmp-pocket-pathology-app   Braun, L.A. et al. (2012) ‘Massage therapy for cardiac surgery patients--a randomized trial', The Journal of Thoracic and Cardiovascular Surgery, 144(6), pp. 1453–1459, 1459.e1. Available at: https://doi.org/10.1016/j.jtcvs.2012.04.027.   Grafton-Clarke, C. et al. (2019) ‘Can postoperative massage therapy reduce pain and anxiety in cardiac surgery patients?', Interactive Cardiovascular and Thoracic Surgery, 28(5), pp. 716–721. Available at: https://doi.org/10.1093/icvts/ivy310.   Patients Who Stay in Hospital Less Than 3 Days After TAVR Fare Better (no date) American College of Cardiology. Available at: https://www.acc.org/about-acc/press-releases/2019/03/04/13/53/http%3a%2f%2fwww.acc.org%2fabout-acc%2fpress-releases%2f2019%2f03%2f04%2f13%2f53%2fpatients-who-stay-in-hospital-less-than-3-days-after-tavr-fare-better (Accessed: 26 September 2024).   Pressler, A. et al. (2018) ‘Long-term effect of exercise training in patients after transcatheter aortic valve implantation: Follow-up of the SPORT:TAVI randomised pilot study', European Journal of Preventive Cardiology, 25(8), pp. 794–801. Available at: https://doi.org/10.1177/2047487318765233.   Transcatheter Aortic Valve Replacement (TAVR) (no date). Available at: https://my.clevelandclinic.org/health/treatments/17570-transcatheter-aortic-valve-replacement-tavr (Accessed: 25 September 2024).   Wang, A.T. et al. (2010) ‘Massage therapy after cardiac surgery', Seminars in Thoracic and Cardiovascular Surgery, 22(3), pp. 225–229. Available at: https://doi.org/10.1053/j.semtcvs.2010.10.005.   What recovery looks like 6 months after an aortic valve replacement (2023). Available at: https://www.medicalnewstoday.com/articles/6-months-after-aortic-valve-replacements (Accessed: 25 September 2024).   Sponsors:   Anatomy Trains: www.anatomytrains.com    Elements Massage: www.elementsmassage.com/abmp   MassageBook: www.massagebook.com   Books of Discovery: www.booksofdiscovery.com   The American Massage Conference: www.massagetherapymedia.com/conferences    

As part of a community health partnership with Valley Health, host Janet Michael welcomes Dr. Ernesto Jimenez from Valley Health's Structural Heart Program team at the Advanced Valve Center on the campus of Winchester Medical Center. They discuss the essentials of the Structural Heart Program, the various heart conditions it addresses, and the innovative procedures now available. Dr. Jimenez provides insights into the program's decade-long history and highlights the collaborative nature of the team, comprised of surgeons, interventional cardiologists, nurses, and other healthcare professionals. He explains how structural heart disease affects the heart's valves and overall function, and the advanced diagnostics and minimally invasive procedures like TAVR (transaortic valve replacement) that have revolutionized treatment. Janet and Dr. Jimenez delve into patient symptoms that may signal valve disease, such as shortness of breath, chest pressure, and leg swelling. They explain the diagnostic process starting from primary care to specialized echocardiograms. Dr. Jimenez assures listeners of the program's top-notch team and the impressive success rates of these lifesaving procedures, which significantly improve patients' survival and quality of life. The discussion also touches on common misconceptions about heart surgery and emphasizes the advancements that make these interventions less daunting, even for elderly patients. Towards the end, Dr. Jimenez expresses optimism for the future of minimally invasive cardiac procedures, predicting greater reliance on such techniques moving forward.  The episode wraps up with a reminder of their top ranking in outcomes within Virginia.

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Radio Advisory first started production in April 2020 to deliver timely, critical messages to healthcare professionals navigating the early days of the Covid-19 pandemic. Four years, 200+ episodes, and one million downloads later, Radio Advisory continues to bring insightful conversations and valuable insights to listeners passionate about driving positive change in healthcare. To celebrate our millionth download, host Rachel (Rae) Woods and the Radio Advisory production team revisit some of their favorite episodes over the last four years, recollect the lessons learned, and reflect on how the healthcare industry has evolved alongside us. We owe this milestone to you, our listeners. Your support and engagement have fueled and enriched our episodes, and we look forward to bringing you many more insightful conversations. Thank you! Links: Ep. 2: How COVID-19 is transforming telehealth now and in the future Ep. 35: Zeke Emanuel on the path to a vaccine (and why it's much harder than you think) Ep. 69: CEO Warner Thomas on 20 years of digital innovation at Ochsner Health Ep. 159: Ozempic, Wegovy, and our questions on weight management drugs 3 paths to the future of obesity care (and how to get there) 5 catalysts that will impact the future of weight management drugs What the headlines get wrong about weight-management medications How Cone Health added ATTR-CM screening to an existing care pathway: A TAVR example A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

David Cohen is one of the smartest docs on Twitter. I learned a bunch talking with him. The procedure called transcatheter aortic valve implantation or TAVR is a damn miracle. In days of old, a heart surgeon would have to saw open the chest and cut out the heavily calcified immobile aortic valve and sew in a new one. I watched a case as a young doctor and came away shocked that patients survive this surgery. TAVR is even more stunning. Doctors place a valve up the aorta, across the diseased valve, and then place the new valve into the old valve. The verbs squishing or smooshing come to mind. The other unbelievable thing about TAVR is that strokes are less common than you'd think. When I first heard about TAVR, I thought: how is it not limited by all that debris going into the brain? Well, there is less debris than I would have thought. But not zero debris. In fact, there is one device on the market that forms a barrier between the aorta and the brain. We call it an embolic protection device (EPD) or cerebral embolic protection (CEP).Early studies show that the device catches debris that would have occluded blood vessels in the brain—iow, caused stroke. The pictures almost sell the device—because, obviously, catching debris has to be beneficial. But. But. There are always ‘but's' in Medicine. The PROTECTED TAVR trial, which compared TAVR with and without an embolic protection device failed to show a statistically significant reduction in stroke. It was a good trial, but it did not close the door for the device. For two reasons: one was that the trial was underpowered. The lower bound of the 95% confidence interval allowed for a 1.7% lower rate of stroke in the treatment arm. Neurologists feel that a 1% risk reduction in stroke is clinically important. The other reason was that a secondary endpoint of “disabling” stroke was 60% lower with the device. We needed more data. Another trial is not likely going to happen. Trials are expensive and take a long time. This is where Dr Cohen's group comes in. They performed an observational study looking at more than 400k patients in a TAVR registry. About 13% got the device and 87% did not. This is where Sensible Medicine readers should start feeling a rash. Why? Because you know how scary it is to try and compare outcomes in two groups of patients who were not randomized. Cohen, however, tells me about a super-interesting way to approximate randomization in this comparison. It's called an instrumental variable analysis. He explains this to me in clear terms during our conversation. I love methods so I was enthralled. But that isn't all. The other thing is that his study, like the PROTECTED TAVR trial, came up with tantalizing close results. We discuss that as well. I loved our talk. If you like evidence, methods, and great medical stories, I think you will also like this conversation. JMMIt's free to all. We appreciate your support for this experiment in bringing ad-free medical information to the public. Sensible Medicine is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. TAVR vs SAVR TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis https://www.medscape.com/viewarticle/tavi-comparable-savr-lower-risk-aortic-stenosis-2024a100074o?form=fpf DEDICATE https://www.nejm.org/doi/full/10.1056/NEJMoa2400685 Partner 3 https://www.nejm.org/doi/full/10.1056/NEJMoa1814052 Evolut Low Risk https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516 II. Renal Denervation Alcohol-Mediated Renal Denervation Promising in Hypertension https://www.medscape.com/viewarticle/alcohol-mediated-renal-denervation-promising-hypertension-2024a10007eg TARGET 1 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069291 III. Inclisiran Earlier Inclisiran Gives Better Long-Term LDL Reductions https://www.medscape.com/viewarticle/earlier-inclisiran-gives-better-long-term-ldl-reductions-2024a10007d6 VICTORIAN INITIATE Trial https://www.jacc.org/doi/10.1016/j.jacc.2024.03.382 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington  Questions or feedback, please contact news@medscape.net